| Literature DB >> 12944915 |
Amir Zalcenstein1, Perry Stambolsky, Lilach Weisz, Martina Müller, David Wallach, Tanya M Goncharov, Peter H Krammer, Varda Rotter, Moshe Oren.
Abstract
Tumor-associated mutant forms of p53 can exert an antiapoptotic gain of function activity, which probably confers a selective advantage upon tumor cells harboring such mutations. We report that mutant p53 suppresses the expression of the CD95 (Fas/APO-1) gene, encoding a death receptor implicated in a variety of apoptotic responses. Moderate (40-50%) downregulation of CD95 mRNA and surface protein expression by mutant p53 correlates with partial protection against CD95-dependent cell death. Excess mutant p53 represses the transcriptional activity of the CD95 promoter, with the extent of repression varying among different tumor-associated p53 mutants. Furthermore, mutant p53 protein binds the CD95 promoter in vitro, in a region distinct from the one implicated in tight interactions of the CD95 gene with wild-type p53. Hence, the CD95 promoter is likely to be a direct target for downregulation by mutant p53. This activity of mutant p53 may contribute to its gain of function effects in oncogenesis.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12944915 DOI: 10.1038/sj.onc.1206724
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867